Literature DB >> 25695376

Lentivirus-mediated knockdown of rhomboid domain containing 1 inhibits colorectal cancer cell growth.

Junyi Han1, Junchao Bai2, Yao Yang3, Hua Yin3, Wei Gao3, Aiguo Lu3, Fei Liu1, Haiyan Ge3, Zhongmin Liu4, Jinyi Wang4, Lan Zhong1.   

Abstract

Rhomboid domain containing 1 (RHBDD1), is a member of the rhomboid protease family, which has a pivotal role in the progression of numerous severe malignancies. However, its role in colorectal carcinoma (CRC) remains to be elucidated. In the present study, RHBDD1 was shown to be widely expressed in CRC cell lines. Lentivirus-mediated RNA interference was employed to knockdown RHBDD1 expression in RKO CRC cells. Functional analyses indicated that depletion of RHBDD1 expression resulted in significantly reduced CRC cell proliferation and colony formation, and induced a G0/G1 phase cell cycle arrest. The findings of the present study suggest that RHBDD1 may contribute to CRC tumorigenesis and serve as a potential therapeutic target in human CRC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25695376     DOI: 10.3892/mmr.2015.3365

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  3 in total

1.  MiR-924 as a tumor suppressor inhibits non-small cell lung cancer by inhibiting RHBDD1/Wnt/β-catenin signaling pathway.

Authors:  Huaishi Wang; Xi Chen; Baishuang Yang; Zhi Xia; Qiong Chen
Journal:  Cancer Cell Int       Date:  2020-10-08       Impact factor: 5.722

2.  Silibinin suppresses epithelial-mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1.

Authors:  Suyan Xu; Hongyan Zhang; Aifeng Wang; Yongcheng Ma; Yuan Gan; Guofeng Li
Journal:  Cell Mol Biol Lett       Date:  2020-06-09       Impact factor: 5.787

3.  Silencing of rhomboid domain containing 1 to inhibit the metastasis of human breast cancer cells in vitro.

Authors:  Chunjun Huang; Xiaochun Ji; Yinyin Peng; Minghua Wu; Weizhu Wu; Yong Luo; Gaoxiang Cheng; Ye Zhu
Journal:  Iran J Basic Med Sci       Date:  2018-11       Impact factor: 2.699

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.